Calibrating COVID-19: The Interplay of Disease Modifying Therapy and Vaccination in Patients with Multiple Sclerosis
Program DescriptionThe emergence of COVID-19 has created an unprecedented medical emergency that both raises new questions and presents updated information each day.
Category
Format
Credits
  • AMA PRA Category 1 Credit™
On Target with “OFF” Therapies: An Exploration of New Agents and Strategies for Parkinson’s Disease
Program DescriptionLevodopa, the gold standard treatment for Parkinson’s disease (PD), is associated with a variety of complications and side effects including motor fluctuations and “OFF” periods.
Category
Format
Credits
  • AMA PRA Category 1 Credit™
Multiple Sclerosis Management: Shedding Light on the Patient Perspective
OverviewThis activity, originally held as a satellite symposium in conjunction with the 2021 Consortium of Multiple Sclerosis (MS) Centers (CMSC) Annual Meeting, is designed to contextualize contemporary management approaches through the documented experiences of people with MS.
Category
Format
  • Self-study / Enduring
Credits
  • AMA PRA Category 1 Credit™
  • ANCC
Devil in the Details: An Expert Guide to Modern Multiple Sclerosis Practices
Program DescriptionThis activity is designed to highlight the differences in self-reported diagnostic and therapeutic strategies of MS specialists and general neurologists.
Category
Format
Credits
  • AMA PRA Category 1 Credit™
The Path of Least Resistance: New Agents and Emerging Strategies for Managing Childhood-Onset and Refractory Epilepsies
Program DescriptionEpilepsy syndromes are historically difficult to diagnose and treat effectively due to their widely varying etiologies and presentations and their high probability of drug-resistance.
Category
Format
Credits
  • AMA PRA Category 1 Credit™
Networks in Neurology: Insights From a Collaborative CME Experience With Practicing Clinicians Regarding New Agents and Strategies for Multiple Sclerosis
Program DescriptionMultiple sclerosis (MS) management has been evolving at a staggering rate for the past two decades, with nearly a third of the 21 available disease modifying therapies (DMTs) receiving their FDA approvals in just the past few years.
Category
Format
Credits
  • AMA PRA Category 1 Credit™
Finding Something in Nothing: Patient-Centered Approaches to Resolve Emotional Blunting in Major Depressive Disorder
Program Description Emotional blunting (EB) is one of the most highly reported and subjectively disruptive symptoms in patients with major depressive disorder (MDD).
Category
Format
Credits
  • AMA PRA Category 1 Credit™
  • Attendance
Module 1: Diagnosis and Progression Monitoring
Module 1: Diagnosis and Therapy InitiationThis module focuses on the timely and accurate diagnosis of MS through maximization of the latest technologies and strategies available.
Category
Format
  • Self-study / Enduring
Credits
Module 2: Initiation and Selection of Disease Modifying Therapy
This module will focus on key clinical factors and practical considerations that may impact DMT initiation as well as utilization of the diverse agents available. Factors discussed include age, radiologic versus clinical disease activity, and usefulness of distinguishing between MS categories.
Category
Format
  • Self-study / Enduring
Credits
Module 3: Navigating Controversy: Prognostic Factors, Breakthroughs, and Biomarkers
This module will focus on topics of debate in the MS arena including best practices in DMT switching, the impact of race and pregnancy on DMT choice, and the potential role of neurofilament light (NfL) in routine practice. 
Category
Format
  • Self-study / Enduring
Credits

Pages